Home
About
Overview
Sharing Data
ORCID
Help
History (9)
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease.
Outcomes after institution of a new oxytocin infusion protocol during the third stage of labor and immediate postpartum period.
Confronting genetic testing disparities: knowledge is power.
Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma.
See All 9 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma.
Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. Clin Cancer Res. 2004 Apr 01; 10(7):2415-20.
View in:
PubMed
subject areas
Biomarkers, Tumor
Blotting, Western
CA-125 Antigen
Carcinoma
Cell-Free System
Culture Media, Conditioned
Female
Humans
Ovarian Neoplasms
Peritoneum
Time Factors
Up-Regulation
authors with profiles
Michael T. Quinn